EnClear Therapies, a Cambridge, MA-based biotechnology company developing device-based therapies for the treatment of neurodegenerative disease, secured approximately $2m in seed funding.
Backers included Thiel Capital, Bioverge, Sanford Biosciences and Christian Angermayer‘s Presight Capital.
The company, which has also hired Kevin Kalish as Vice President of Research and Development, intends to use the funds to advance development of its therapies.
Led by Anthony DePasqua, Chief Executive Officer and Co-founder, EnClear Therapies is a biotechnology company developing neurology-focused, device-based systems that remove toxic proteins as therapies for the treatment of neurodegenerative diseases and provide closed loop delivery & monitoring of cerebrospinal fluids (CSF).
The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).